Fig. 3.
Epitope mapping of the anti-BPTP901-1 nanobodies performed by SPR. (A) Anti-BppL nanobodies. (B) Anti-BppU nanobodies. (A) BppL and (B) BppU were injected over the immobilized nanobodies (Chip) as positive controls (white) and have been normalized to 100. Then, (A) BppL and (B) BppU were injected in presence of the different anti-BppL and anti-BppU nanobodies, and the response signal was normalized to the positive control. *Nanobodies presenting a response pattern dissimilar to the other patterns.